This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Identify the Dividend Aristocrats ETF with the lowest fees and understand how fee selection affects long-term performance.
27,609 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Bitcoin holds near $62,000 as inflation jitters and geopolitical risk tie markets in knots. The crypto narrative arou...
Insider stock moves can be routine or signaling. This article breaks down the facts behind ford's farley sells 6,454,...
Start your week with purpose. These Monday reads distill market signals, tech shifts, and personal-finance moves into...
A notable fund trimmed a sizable healthcare stake by roughly $6.5 million as the stock soared and revenue grew. Here’...
As the chip index climbs, fund managers sit on a cautious chair, weighing gains against risk. Bank of America flags p...
Volatility is rising and daily balance checks may hurt more than help. This piece explains why experts stop checking ...
As portfolios tilt toward a handful of tech giants, AVUV provides a diversified counterweight. This story explains ho...
Silver markets tighten as COMEX inventories shrink and the pricing curve tightens. Traders ask how long the exchange ...
Bitcoin tumbles from a multi-month uptrend but buyers defend the $60,000 zone. This week will reveal whether BTC can ...
Institutional moves can reshape a niche tech stock overnight. This article breaks down the recent liquidation by Loun...
A sweeping shift shows crypto institutional flows turning negative, with about $8 billion pulled from BTC ETFs, stabl...